A UCL study finds a genomic test can identify high-risk prostate cancer patients who benefit from adding abiraterone to standard care, aiding treatment decisions by predicting metastasis and mortality risk.
NeoGenomics has launched the first FDA-approved PTEN IHC companion diagnostic for prostate adenocarcinoma, enabling identification of patients with PTEN deficiency who may benefit from AstraZeneca’s capivasertib therapy.
The tissue- and blood-based tests identify patients with specific gene mutations who may benefit from a combination therapy.
Veracyte will present over 15 studies on its Decipher prostate and bladder cancer tests, including new clinical trial data, at the 2026 ASCO Genitourinary Cancers Symposium in San Francisco.
Read More
A genomic test widely used in prostate cancer care can more accurately identify which men with early-stage disease face high risk of recurrence after treatment.
Read More
The test receives premarket approval as an aid in biopsy decision-making for men 50 and older with elevated PSA levels.
Read More
The whole-genome test combines data from 7 million genetic markers with clinical risk factors to provide individualized 10-year and lifetime risk assessments.
Read More
Research demonstrates 13% relative reduction in prostate cancer deaths but highlights overdiagnosis concerns, prompting calls for risk-based screening approaches.
Read More
A study of over 10 million men reveals frequent testing of patients unlikely to benefit, raising questions about current screening practices.
Read More
PROSTOX ultra identifies patients at higher risk of developing late genitourinary toxicity from stereotactic body radiation therapy.
Read More
Study finds molecular signature identifies which men with recurrent disease respond to apalutamide plus salvage radiation therapy.
Read More
Phase 3 STAMPEDE trial data demonstrates Decipher Prostate test can predict docetaxel treatment benefit, potentially helping patients avoid unnecessary toxicity.
Read More
The risk stratification tool is designed to predict long-term outcomes for patients with non-metastatic prostate cancer.
Read More
Fellow Health showcased innovative research, emphasizing mail-in semen testing to enhance prostate cancer diagnostics and PVSA care.
Read More
Veracyte has launched Decipher Prostate test, a Medicare-covered test for guiding treatment in metastatic prostate cancer.
Read More
A new study confirms Cleveland Diagnostics’ IsoPSA test effectively differentiates between low- and high-risk prostate cancer patients.
Read More
Decipher Prostate Genomic Classifier data is included in a new SEER Program database, enabling the study of prostate cancer outcomes.
Read More
Lynx Dx announced at-home availability of a urine-based prostate cancer test that eliminates the need for a digital rectal exam.
Read More